Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

Hello, readers! Welcome to a bonus letters column. We are happy to report that you are keeping our inboxes busy, so we’ll dive right in.

Scientists have uncovered a molecular "on–off" switch that helps lung adenocarcinoma—the most common form of lung cancer—grow and spread. The discovery pinpoints the protein calcyclin ...

A meta-analysis of nearly 3.9 million participants shows people with allergies have significantly lower odds of developing lung cancer. Allergic rhinitis is particularly protective, while eczema’s ...

Non-small cell lung cancer (NSCLC) develops in lung tissues, but when it's metastatic, it has spread to distant areas of the body, such as the bones or liver.

Clinical study results demonstrated that CyPath® Lung had 92% sensitivity, 87% specificity and 88% accuracy in detecting lung cancer in patients at high risk for the disease who had small lung ...

Lung cancer, the second-most common cancer in the U.S., is often associated with smoking — but even those who have never had a cigarette could be at risk of the deadly disease.

β-Glucan-mediated trained immunity activates alveolar macrophages which exacerbates acute lung injury induced by LPS.

Exposure to a common fungal molecule can reprogram immune cells in the lungs, causing them to overreact to infection-like signals and worsen lung damage, according to new research.

The FDA has granted quick approval to sunvozertinib (sold as Zegfrovy) a first-of-its-kind pill for a type of lung cancer known as non-small-cell lung cancer (NSCLC).

Early-stage lung cancer sometimes causes finger clubbing, a harmless symptom that usually resolves when the cancer is treated.